California State Teachers Retirement System Grows Position in Krystal Biotech, Inc. $KRYS

Posted by Brenda Bartman on Sep 11th, 2026

California State Teachers Retirement System increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 33,527.2% in the second quarter, Holdings Channel reports. The firm owned 8,805,606 shares of the company’s stock after buying an additional 8,779,420 shares during the period. California State Teachers Retirement System owned about 0.30% of Krystal Biotech worth $3,272,780,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Silvant Capital Management LLC acquired a new position in Krystal Biotech in the second quarter valued at about $30,000. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the first quarter valued at about $34,000. Greenline Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the fourth quarter valued at about $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech in the 3rd quarter valued at approximately $35,000. Finally, UMB Bank n.a. raised its stake in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Dino Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock worth $17,558,270. Corporate insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of several recent analyst reports. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. Citigroup boosted their target price on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, TD Cowen raised their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $365.40.

Get Our Latest Stock Report on KRYS

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $345.55 on Friday. The stock has a market capitalization of $10.23 billion, a P/E ratio of 43.30 and a beta of 0.54. The company has a 50 day moving average price of $347.95 and a 200 day moving average price of $309.76. Krystal Biotech, Inc. has a fifty-two week low of $137.02 and a fifty-two week high of $382.54.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Krystal Biotech Profile

(Free Report)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.